Related Experiment Video

Updated: Jun 26, 2025

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.0K

GLP-1 receptor agonist improves metabolic disease in a pre-clinical model of lipodystrophy

Ahlima Roumane1, George D Mcilroy1, Nadine Sommer1

  • 1The Rowett Institute and Aberdeen Cardiovascular and Diabetes Centre, University of Aberdeen, Aberdeen, United Kingdom.

Frontiers in Endocrinology
|May 15, 2024
PubMed
Abstract

Insights

Glucagon-like peptide-1 receptor (GLP-1R) agonist liraglutide improved lipoatrophic diabetes and liver steatosis in mice. This suggests GLP-1R agonists may offer new therapeutic options for lipodystrophy patients.

Area of Science:

  • Metabolic disease research
  • Pharmacology
  • Endocrinology

Background:

  • Lipodystrophies involve adipose tissue dysfunction, leading to metabolic diseases like lipoatrophic diabetes.
  • Congenital generalized lipodystrophy, a severe form, is characterized by near-complete absence of adipose tissue.
  • Current therapies for lipodystrophy are limited, necessitating novel treatment strategies.

Purpose of the Study:

  • To investigate the therapeutic effects of a glucagon-like peptide-1 receptor (GLP-1R) agonist in a mouse model of lipoatrophic diabetes.
  • To assess the impact of liraglutide on insulin resistance, glucose intolerance, and liver pathology in generalized lipodystrophy.

Main Methods:

  • Seipin knockout mice, exhibiting lipodystrophy, insulin resistance, and glucose intolerance, were treated with the GLP-1R agonist liraglutide.
  • Treatments included acute administration before tolerance tests and chronic daily injections for 14 days.
  • Metabolic phenotyping and ex vivo studies were conducted to evaluate treatment efficacy.

Main Results:

  • Acute liraglutide treatment significantly enhanced insulin, glucose, and pyruvate tolerance.
  • Chronic liraglutide administration reduced liver enlargement (hepatomegaly) and steatosis, alongside decreased liver fibrosis markers.
  • Liraglutide improved glucose control and stimulated insulin secretion in response to glucose challenges.

Conclusions:

  • The GLP-1R agonist liraglutide demonstrated significant improvements in lipoatrophic diabetes and hepatic steatosis in mice with generalized lipodystrophy.
  • These findings highlight the potential of GLP-1R agonists as a therapeutic approach for managing lipodystrophy.
  • This research provides valuable insights for the broader application of GLP-1R agonists to improve patient health outcomes.
Keywords:
diabetesglucagon-like peptide-1lipodystrophyliraglutideseipin

More Related Videos

A Model of Chronic Nutrient Infusion in the Rat08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

12.7K
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

11.9K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
318
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
153
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
1.4K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192